Related Experiment Videos
Is reseeding from the primary a plausible cause of node failure?
B M Dubray1, J P Bataini, J Bernier
1Department of Biomathematics, M.D. Anderson Cancer Center, Houston, TX 77033.
International Journal of Radiation Oncology, Biology, Physics
|January 1, 1993
Summary
Node failures in oropharyngeal cancer are often not due to primary tumor spread. Including all patients, even those with low radiotherapy doses, improves understanding of nodal failure in squamous cell carcinomas.
Area of Science:
- Oncology
- Radiation Oncology
- Head and Neck Cancers
Background:
- Previous analyses excluded patients with node recurrence linked to primary failure or low radiotherapy doses (<55 Gy).
- This exclusion significantly reduced the observed rate of node failures, potentially skewing results.
Purpose of the Study:
- To re-evaluate nodal failure in oropharyngeal and pharyngolaryngeal squamous cell carcinomas by including all patients.
- To determine factors influencing nodal failure and the impact of excluding low-dose treatments.
Main Methods:
- Analysis of 1251 patients with node-positive oropharyngeal and pharyngolaryngeal squamous cell carcinomas treated with external radiotherapy.
- Inclusion of all patients, regardless of primary failure association or received dose, for comprehensive analysis.
Main Results:
- When all patients were included, nodal failure probability increased with larger nodes, T4 primaries, lower nodal doses, contralateral metastases, and nodal fixation.
- A significant dose-control relationship was lost when low-dose treatments (<55 Gy) were excluded.
- 60% of node recurrences associated with primary failure occurred within one month post-irradiation, suggesting they were not from primary tumor reseeding.
Conclusions:
- The majority of nodal failures are unlikely to originate from primary tumor reseeding and should be included in local-control analyses.
- Excluding palliative, low-dose treatments hinders the understanding of dose-response relationships in radiotherapy for head and neck cancers.